Comparison of outcomes parameters for induction of remission in new onset pediatric Crohn's disease: Evaluation of the porto IBD group "growth relapse and outcomes with therapy" (GROWTH CD) study

Inflammatory Bowel Diseases

Volumn 20, Issue 2, 2014, Pages 278-285

  Levine, Arie ^a   Turner, Dan ^b,c   Gik, Tamar Pfeffer ^a,c   Dias, Jorge Amil ^d   Veres, Gabor ^e   Shaoul, Ron ^f   Staiano, Annamaria ^g   Escher, Johanna ^h   Kolho, Kaija Leena ⁱ   Paerregaard, Anders ^j   De Carpi, Javier Martin ^k   Wauters, Gigi Veereman ^l   Koletzko, Sibylle ^m   Shevah, Orit ^a   Finnby, Lenne ⁿ   Sladek, Malgorzata ^o  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHAARE ZEDEK MEDICAL CENTER   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f MEYER CHILDREN S HOSPITAL   (Israel)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h SOPHIA CHILDREN S HOSPITAL   (Netherlands)

ⁱ UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^j HVIDOVRE HOSPITAL   (Denmark)

^k HOSPITAL SANT JOAN DE DÉU   (Spain)

^l UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^m LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁿ LOVISENBERG DIAKONALE HOSPITAL   (Norway)

^o JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

more..

Author keywords

Biomarkers; C reactive protein; Crohn's disease; Exclusive enteral nutrition; Outcomes; Relapse; Treatment

Indexed keywords

AZATHIOPRINE; BUDESONIDE; C REACTIVE PROTEIN; CALGRANULIN; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; PREDNISONE; STEROID; GLUCOCORTICOID; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR;

ARTICLE; CHILD; CHILDHOOD DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE REDUCTION; ENTERIC FEEDING; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOMODULATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELAPSE; REMISSION; SCHOOL CHILD; ADOLESCENT; ANTAGONISTS AND INHIBITORS; COLONOSCOPY; COMPARATIVE STUDY; EUROPE; FOLLOW UP; INFLAMMATORY BOWEL DISEASES; ISRAEL; ONSET AGE; PROCEDURES; RECURRENT DISEASE; TIME FACTOR; TREATMENT OUTCOME;

ADOLESCENT; AGE OF ONSET; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; CHILD; COLONOSCOPY; CROHN DISEASE; EUROPE; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; ISRAEL; MALE; PREDNISONE; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893761513     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000437735.11953.68     Document Type: Article

References (33)

1. Lewis J. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011;140:1817-1826.
2. Cosnes J, Gower Rousseau C, Seksik P, et al. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140: 1785-1794.
3. Gupta N, Cohen S, Bostrom A, et al. Risk factor for initial surgery in pediatric patients with Crohn's disease. Gastroenterology. 2006;130: 1069-1077.
4. Van Limbergen J, Russell R, Drummond H, et al. Definition of phenotypic characteristics of childhood onset inflammatory bowel disease. Gastroenterol. 2008;135:1114-1122.
5. Shaoul R, Karban A, Reif S, et al. Disease behavior in children with Crohn's disease the effect of disease duration ethnicity genotype and phenotype. Dig Dis Sci. 2009;52:142-150.
6. Gupta N, Bostrom A, Kirschner B, et al. Presentation and disease course in early- compared to later-onset pediatric Crohn's disease. Am J Gastroenterol. 2008;103:2092-2098.
7. Shamir R, Phillip M, Levine A. Growth retardation in pediatric Crohn's disease: pathogenesis and interventions. Inflamm Bowel Dis. 2007;13: 620-628.
8. Van Assche G, Dignass A, Reinisch W, et al. The second European evidencebased consensus on the diagnosis and management of Crohn's disease special situations. J Crohn's Colitis. 2010;4:63-101.
9. Dziechiciarz P, Horvath A, Shamir R, et al. Meta-analysis of enteral nutrition in active Crohn's disease in children. Aliment Pharmacol Therap. 2007; 26:795-806.
10. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Sys Rev, 2007;1:CD000542
11. Rubio A, Pigneur B, Garnier-Lengline H, et al. The efficacy of exclusive nutritional therapy in paediatric Crohn's disease comparing fractionated oral vs. continuous enteral feeding. Aliment Pharmacol Ther. 2011;33: 1332-1339.
12. Heuschkel R. Enteral nutrition should be used to induce remission in childhood Crohn's Disease. Dig Dis. 2009;27:297-305.
13. Critch J, Day AS, Otley A, et al. Use of enteral nutrition for the control of intestinal inflammation in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2012;54:298-305.
14. Gisbert JP, Bermejo F, Pérez-Calle J, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15:1190-1198.
15. Kiss L, Szamos T, Molnar T. Early clinical remission and normalization of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther. 2011;34:911-922.
16. Reinisch W, Wang Y, Odden J, et al. C reactive protein an indicator for maintained response or remission to infliximab in patients with Crohn's disease a post hoc analysis from ACCENT I. Aliment Pharmacol Ther. 2012;35:568-576.
17. Roseth A, Aadland E, Grzyb K. Normalization of faecal calprotectin a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004;39:1017-1020.
18. Lakatos PL. Prediction of disease course in inflammatory bowel diseases. World J Gastroenterol. 2010;16:2589-2590.
19. IBD Working Group of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). Inflammatory bowel disease in children and adolescents recommendations for diagnosis the Porto criteria. J Pediatr Gastroenterol Nutr. 2005;41:1-7.
20. Levine A, Griffiths A, Markowitz J, et al. Pediatric modification of the Montreal classification for inflammatory bowel disease the Paris classification. Inflamm Bowel Dis. 2011;17:1314-1321.
21. Turner D, Griffiths A, Walters D. Mathematical weighting of the pediatric Crohn's disease activity index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis. 2012;18:55-62.
22. Kallel L, Ayadi I, Marti S. Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon a prospective study. Eur J Gastroenterol Hepatol. 2010;22:340-345.
23. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998; 17:2265-2281.
24. Brookhart MA, Schneeweiss S, Rothman KJ, et al. Variable selection for propensity scoremodels. Am J Epidemiol. 2006;163:1149-1156.
25. Molander P, Björkesten CG, Mustonen H, et al. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFa blocking agents. Inflamm Bowel Dis. 2012;18:2011-2017.
26. Boschetti G, Preaudat C, Charloisl A. Assessment of response to therapy with TNF alpha blocking agents by calprotectin and S100A12 protein concentrations in serum and tools in patients with Crohn's disease. Gut. 2012;61(Suppl 3A):160.
27. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early stage Crohn's disease. Gastroenterology. 2010;138:463-468.
28. De Cruz P, Kamm MA, Prideaux L, et al. Mucosal healing in Crohn's disease: a systematic review. Inflamm Bowel Dis. 2013;19:429-444.
29. Neurath M, Travis. Mucosal healing in inflammatory bowel diseases: systematic review. Gut. 2012;61:1619-1635.
30. Mao R, Xiao Y, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18:1894-1899.
31. Jurgens M, John J, Cleynen I, et al. Levels of C reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2011;9:421-427.
32. Mesker T, Rheenen P, Norbruis O, et al. Pediatric Crohn's disease activity at diagnosis its influence on pediatrician's prescribing behavior and clinical outcome five years later. inflamm bowel dis. 2009;115:1670-1677.
33. Laharie D, Mesli S, Hajbi F, et al. Prediction of Crohn's disease relapse with fecal calprotectin in infliximab responders a prospective study. Aliment Pharmacol Ther. 2011;34:462.